Progress in Venous Thromboembolism Research

A special issue of Medicina (ISSN 1648-9144).

Deadline for manuscript submissions: 31 October 2025 | Viewed by 230

Special Issue Editor


E-Mail Website
Guest Editor
Department of Internal Medicine, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania
Interests: hypertension; atrial fibrillation; heart failure; venous thromboembolism (deep vein thrombosis, pulmonary thromboembolism); thrombophilias
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Venous thromboembolism (VTE) is the third most frequent cardiovascular disease after myocardial infarction and ischemic stroke. The burden of disease is enormous, considering the risk of death and complications such as recurrence, post-thrombotic syndrome, chronic thromboembolic pulmonary disease, or bleeding while on anticoagulants.

Despite these, VTE is a preventable disease. Progress in reducing the disease burden both through prevention and treatment has been made during recent years. The development of risk assessment models allows for a better selection of patients for prophylaxis. Choosing the appropriate medications, doses and duration of prophylaxis are very important steps in patient management for both inpatients and outpatients.

Improvement of the diagnosis algorithm will decrease the costs and the number of misdiagnosed cases.

Progress in treatment strategies (medical and interventional) will minimize mortality and morbidity. New anticoagulant drugs targeting factor XI are being evaluated in phase 3 clinical trials in people with atrial fibrillation. Their future use in patients with VTE will mark a big step forward that may improve outcomes in this population.

Considering the above, I propose this Special Issue on the Progress in Venous Thromboembolism Research, which will focus on progress in prevention, diagnosis, treatment, and prevention of complications.

Dr. Mihaela Hostiuc
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • venous thromboembolism
  • cardiovascular disease
  • post-thrombotic syndrome
  • chronic thromboembolic pulmonary disease
  • prevention

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

23 pages, 451 KiB  
Review
Etiology and Risk Factors for Splanchnic Vein Thrombosis in Non-Cirrhotic, Non-Neoplastic Patients: A Narrative Review
by Mihaela Hostiuc and Ionut Negoi
Medicina 2025, 61(5), 933; https://doi.org/10.3390/medicina61050933 - 21 May 2025
Viewed by 97
Abstract
Splanchnic vein thrombosis (SVT) is a heterogeneous group of disorders affecting the portal, mesenteric, splenic, and hepatic veins. While frequently associated with liver cirrhosis and malignancy, SVT also occurs in non-cirrhotic, non-neoplastic patients. This narrative review evaluates the epidemiology and risk factors for [...] Read more.
Splanchnic vein thrombosis (SVT) is a heterogeneous group of disorders affecting the portal, mesenteric, splenic, and hepatic veins. While frequently associated with liver cirrhosis and malignancy, SVT also occurs in non-cirrhotic, non-neoplastic patients. This narrative review evaluates the epidemiology and risk factors for SVT in this population. The prevalence and incidence of SVT in non-cirrhotic, non-neoplastic patients remain incompletely characterized, with estimates varying widely across studies. The clinical significance of SVT relates to potential complications, including intestinal ischemia, portal hypertension, and a possible underlying systemic disorder. Risk factors for SVT can be categorized into local abdominal conditions, thrombophilias, and systemic disorders. Local factors include inflammatory bowel disease, pancreatitis, abdominal surgery, and trauma. Thrombophilias, both inherited and acquired, are significant contributors to SVT risk. Systemic conditions associated with SVT include autoimmune disorders, pregnancy, hematological diseases, and infections. The complex interplay of these risk factors highlights the need for a comprehensive evaluation of SVT patients. Early recognition and management of these conditions can prevent potentially life-threatening complications and guide decisions regarding anticoagulation and long-term follow-up. Full article
(This article belongs to the Special Issue Progress in Venous Thromboembolism Research)
Back to TopTop